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We investigated a number of biological markers, evaluated under strict intralaboratory quality control conditions, in terms of
their role in predicting clinical outcome of patients with colon cancer treated with 5-FU-containing regimens. Colon cancer
tissue from 263 patients enrolled onto two randomised clinical trials were studied for their cytoﬂuorimetrically determined
DNA content and their immunohistochemically evaluated microvessel density, vascular endothelial growth factor expression,
thymidylate synthase expression and tumour lymphocyte inﬁltration. Disease-free survival and overall survival of patients were
analysed as a function of the different variables. At a median follow up of 57 months, age, gender and Dukes’ stage showed an
impact on disease-free survival, whereas no biological marker emerged as an indicator of better or worse disease-free survival.
Only histological grade and Dukes’ stage were found to inﬂuence overall survival. The different biological variables, studied
with particular attention for determination reliability, proved to have no impact on the clinical outcome of patients with colon
cancer. Therefore, other markers must be identiﬁed to complement clinico-pathological variables in the management of this
disease.
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Clinical experiences have repeatedly shown that colon cancers of
the same histotype or at the same pathological stage have a differ-
ent clinical outcome and may respond differently to chemotherapy.
In the last 20 years researchers have tried to identify biological
markers capable of predicting clinical outcome and tumour sensi-
tivity or resistance to cytotoxic drugs.
The ﬁrst studies focused mainly on cellular features such as cell
proliferation and DNA ploidy, but since then genetic alterations
(p53, K-ras, deletions involving chromosome 18q, microsatellite
instability), enzymatic activities (thymidylate synthase (TS)), dihy-
dropyrimidine dehydrogenase, thymidine phosphorylase,
neoangiogenesis-related markers (vascular endothelial growth
factor (VEGF), microvessel density (MVD)) and lymphocyte inﬁl-
tration have been investigated.
Controversial results have been obtained and almost all these
variables have been classed as category IIB (well studied but not
sufﬁcient for category I or IIA) or category III (not yet studied
sufﬁciently to meet criteria for category I, IIA or IIB) by the Amer-
ican Joint Committee on Cancer Prognostic Factors Consensus
Conference (Compton et al, 2000). The main limitations of the
studies are the small sample size and heterogeneity of case series.
Furthermore, only speciﬁc groups of markers have been investi-
gated in individual studies.
In the present study a number of biological markers, larger than
any previously investigated and selected among those considered as
the most promising for their potential role as prognostic variable
or indicator of response to chemotherapeutic regimens, were deter-
mined in parallel on each tumour.
In particular, in a cohort of 330 patients enrolled onto two
randomised studies and given 5-FU-containing chemotherapeutic
associations with different modulators (levamisole, folinic acid,
methotrexate), MVD, VEGF expression, cytoﬂuorimetrically-deter-
mined nuclear DNA content (ploidy), tumour lymphocyte
inﬁltration and TS expression were analysed together with conven-
tional clinico-pathological variables. We decided not to include p53
expression, which for some time has been the object of consider-
able research, in our biologic characterisation as our own
experience and that of other authors did not leave us conﬁdent
about the reliability of results obtainable from samples histologi-
cally ﬁxed for uncontrolled and variable times (Daidone et al,
1998).
The series of patients was recruited by one of ﬁve cooperative
groups taking part in two multicenter randomised clinical proto-
cols (Di Costanzo et al, 1999).
Given the contradictory results on the clinical relevance of
biological markers, special attention was paid to determination
reproducibility through strict intralaboratory quality controls.
MATERIALS AND METHODS
Patients
From March 1992 to December 1998 ﬁve Italian cooperative
groups conducted two large national multicentre randomised clin-
ical trials on adjuvant chemotherapy in colon cancer. In both
studies eligibility criteria were as follows: histologically proven
and radically resected primary intraperitoneal colon adenocarcino-
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52. The deﬁnition of colon cancer included any lesion of the large
bowel that did not require the opening of the pelvic peritoneum to
deﬁne the distal extent of the tumour and/or any lesion localised at
12 cm from the pectinate line. The inferior margin of the tumour
had to be above the peritoneal reﬂection. The absence of metas-
tases had to be ascertained before randomisation by liver
ultrasonography or CT scan, chest X-ray and exploratory laparat-
omy during surgery.
The ﬁrst trial, INTACC 01 (1703 patients), was concluded in
February 1995. Patients were randomised as follows: arm A, 5-
ﬂuorouracil (5-FU) 450 mg m
72 i.v. bolus on days 1–5+levami-
sole (LEVA) 150 mg per os on days 1–3; arm B, 5-FU
370 mg m
72 i.v. bolus on days 1–5 preceded by an i.v. bolus of
6-S-leucovorin (6-S-LV) 100 mg m
72 on days 1–5+LEVA given
as in arm A. In both arms, 5-FU courses were repeated at 4-week
intervals for six cycles and LEVA was given every other week for a
total of 24 weeks (Di Costanzo et al, 1999)
INTACC 02, activated in February 1995 and concluded in
December 1998, recruited 1945 patients. Patients were randomised
as follows: arm A, as arm B of INTACC 01; arm B, methotrexate
(MTX) 40 mg m
72 i.v. bolus on days 1 and 8, 5-FU
600 mg m
72 i.v. bolus on days 2 and 9, LEVA 150 mg per os
on days 1–3. In both arms, 5-FU courses were repeated at 4-week
intervals for six cycles and LEVA was given every other week for a
total of 24 weeks (Lionetto, 1999).
For both studies, clinical data were collected at the time of
randomisation, which was carried out within 60 days of surgery.
The study was examined and approved by the Ethics Committee
of the Local Health and Social Services of each centre in accor-
dance with the ethical standards laid down in the 1964
Declaration of Helsinki. All patients gave oral or written informed
consent.
Randomisation procedures were carried out within individual
cooperative groups. Timing and dose modiﬁcation were planned
on the basis of toxicity registered.
A clinical, haematological, instrumental (chest X-ray, and liver
ultrasonography or CT scan) and biochemical assessment for each
patient was performed at 6-month intervals for the ﬁrst 2 years,
after which all examinations were carried out once a year. In addi-
tion, following randomisation, all patients underwent an annual
barium enema and/or colonscopy.
A total of 330 patients were recruited from March 1992 to
December 1998 by Istituto Oncologico Romagnolo, one of the ﬁve
Italian cooperative groups participating in INTACC 01 and
INTACC 02.
In vitro determinations
Parafﬁn-embedded histological blocks were available for 263 of the
330 randomised cases.
On the basis of the priority of biological determinations, the
amount of available tumour material and determination feasibility,
information on TS was available for 257 patients, on lymphocyte
inﬁltration for 256, on MVD for 251, on ploidy for 243 and on
VEGF for 187. All biological determinations were carried out in
only one laboratory (Forlı `), which participates, for ploidy, or is
the coordinating center, for MVD, in national Quality Control
Programmes. For lymphocyte inﬁltration, VEGF and TS, the relia-
bility and reproducibility of results were guaranteed by blind
determination performed by at least two observers.
Immunohistochemical determinations
Tumour samples were ﬁxed in 10% formalin. Four-micrometre
sections were mounted on positive-charged slides (Bio-Optica,
Milan, Italy), deparafﬁnised with xylene, rehydrated and endogen-
ous peroxidase activity was blocked by 3% hydrogen peroxide
solution. After adequate antigen retrieval, the sections were treated
for non-speciﬁc binding with 3% bovine serum albumin in PBS for
20 min and then incubated for 1 h at room temperature with
primary antibodies. The sections were washed with PBS and incu-
bated with biotinylated anti-mouse secondary antibody. After
rinsing with PBS, sections were incubated with streptavidin-perox-
idase conjugate (Dako Corporation, LSAB+ kit, Carpinteria, CA,
USA). Sections were then rinsed in PBS, and antibody binding
was detected by staining with diaminobenzidine/hydrogen peroxi-
dase chromogen solution (DAB+, liquid substrate-chromogen
solution, Dako Corporation). Sections were rinsed in deionised
water, cell nuclei were counterstained blue by Mayer’s Haemalum
and the sections were mounted in Eukitt (Bio-Optica).
For microvessel density determination, sections were incubated
with polyclonal antibody against human Factor VIII-related antigen
(Dako Corporation) at a 1:300 dilution in PBS containing 10%
goat serum for 30 min at room temperature. After washing in
PBS, sections were incubated with an antirabbit biotinylated anti-
body and positivity detected by an immunoperoxidase reaction
(Kit Supersensitive, Biogenex, San Ramon, CA, USA) for 20 min.
Blood vessels within the tissue were used as a positive internal
control for Factor VIII positivity. Each set of samples contained
a negative control in which primary antibody was omitted.
MVD, evaluated by scoring contiguous ﬁelds, was expressed acc-
ording to Weidner’s method as the number of microvessels mm
72
(Medri et al, 2000). The scoring and count were performed blindly
by two observers. The laboratory (Forlı `) where MVD was deter-
mined is the Reference Center for a National Quality Control
Programme sponsored by the Italian Ministry of Health.
Thymidylate Synthase expression was determined using a mono-
clonal antibody (clone 106, Neomarker, Union City, CA, USA) that
speciﬁcally reacts with TS protein in formalin-ﬁxed, parafﬁn-
embedded human tissue, at a dilution of 1:80 in PBS. TS antigen
retrieval was performed by microwaving the slides at 600 W for
18 min in 10 mM citrate buffer (pH 6.0) followed by cooling at
room temperature for at least 20 min. Control tumour slides
(LoVo and WiDr tumour cell lines) were stained in parallel with
the antibody. Immune serum was omitted in negative controls.
Vascular endothelial growth factor expression was determined
using a pre-diluted polyclonal antibody that speciﬁcally reacts with
VEGF isoforms 121, 165, 189, and 206 in formalin-ﬁxed, parafﬁn-
embedded human tissue (Biogenex, San Ramon, CA, USA). VEGF
antigen retrieval was performed by microwaving the slides at
750 W for 15 min in 10 mM citrate buffer (pH 6.0) followed by
cooling at room temperature for at least 20 min. Control tumour
slides (HL-60 and K562 tumour cell lines) were stained in parallel
with the antibody. Immune serum was omitted in negative
controls.
For both VEGF and TS determinations, each section was scored
by two separate observers (FDP, AMG) at light-microscope (2006
and 4006) and, in cases when the difference exceeded 10%, by a
third observer. Immunoreactivity was expressed as the ratio
between the percentage of immunopositive areas in relation to
the whole section of invasive neoplastic tissue. The expression
was also quantitated using a grading system based on intensity of
staining (0–3).
Tumor lymphocyte inﬁltration was evaluated semi-quantitatively
as absent, poor, moderate or marked (0 to 3).
Flow cytometric analysis was performed on cell suspensions
obtained from 50-mm parafﬁn-embedded sections using a modiﬁed
version of the procedure developed by Hedley et al (1983). Brieﬂy,
tissue was minced, digested in 1% pepsin solution, pH 1.5, for
30 min at 378C. Cells were then resuspended in RPMI, ﬁltered
through a disposable 40 mm ﬁlter assembly (RATCOM) and disgre-
gated nuclei were incubated with 500 ml of Bauer solution, pH 7.2
(RNAse) (0.2 Ku ml
71), PEG 8000 (30 mg ml
71), tri-Sodium
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71), Triton X-100 (100 mgm l
71) and propi-
dium iodide (2.5 mgm l
71)) for 20 min at 378C.
Nuclei were stained with 500 ml of a solution containing propi-
dium iodide (25 mgm l
71), PEG 8000 (300 mg ml
71), Triton X-
100 (100 mgm l
71) and NaCl (9.4 mg ml
71). The samples were
stored for 30–60 min before ﬂow cytometric analysis.
All samples were analysed using FACS Vantage ﬂow cytometer
(Becton Dickinson; San Jose, CA, USA) equipped with a water-
cooled argon-ion laser. Data acquisition was performed using
CELLQuest software and for each sample at least 30000 events
were collected and stored for subsequent analysis. Data were elabo-
rated using Modﬁt (DNA Modelling System) software and
expressed as fractions of cells in the different cycle phases. A histo-
gram was considered interpretable if the coefﬁcient of variation of
the G0/G1 peak was less than 5%. DNA ploidy was deﬁned as DNA
Index (DI) and tumours with a DI=1 were considered to be aneu-
ploid.
Statistical analysis
The relationship between VEGF, TS, MVD and clinico-pathological
or biological characteristics was analysed using a non-parametric
ranking statistic (Median test), and the Spearman’s correlation
coefﬁcient (rs) was used to investigate the relation between the
different biological markers considered as continuous variables.
DFS was calculated as the period from the date of surgery until
the ﬁrst documented evidence of new disease manifestation in
locoregional or distant sites, death due to any cause or occurrence
of a new non-colorectal malignancy. For OS, death due to any
cause was considered as an event. Four-year DFS and OS and
the 95% Conﬁdence Interval (95%CI) were obtained using
Kaplan-Meier estimates (Kaplan, Meier, 1958). The median follow
up of the entire cases series of 263 patients entered onto the biolo-
gic characterisation study was 57 months (range 2–104).
The possible role of the quantitative markers (VEGF, TS, MVD)
in inﬂuencing clinical outcome was studied by analysing each of
them as continuous and dichotomous variables. Median values
were used as cut-off to identify groups with different risk of relapse
or death.
The null hypothesis concerning the different impact of each
dichotomized biologic marker on clinical outcome was tested in
univariate analysis by a stratiﬁed logrank test, according to treat-
ment schedule. This stratiﬁcation allowed to adjust for possible
confounding effects of treatment on clinical outcome, although it
must be pointed out that all treatment combinations contained
5-FU and differed only in the modulating compound (LEVA, 6-
S-LV, Methotrexate). Furthermore, the clinical results from
INTACC 01 did not highlight any difference between the two arms.
The impact of each biological marker on clinical outcome was also
analysed in different Cox regression models, stratiﬁed by treatment
schedule and containing age, gender, Dukes’ stage and histological
grade.
All P values were based on two-sided testing and statistical
analyses were carried out with SAS Statistical Software (SAS Insti-
tute Inc., 1989).
RESULTS
The clinical, pathological and biological features of the 263 patients
for whom parafﬁn-embedded archive material was available for
biological characterisation are reported in Table 1.
Median age was 60 years (range 28–79) and males and females,
as well as patients with Dukes’ Stage B or C tumours, were evenly
distributed in the case series. About 60% of tumours were localised
in the distal tract of the colon and more than two-thirds of lesions
were well or moderately differentiated. More than 80% of patients
had a good Performance Status (ECOG=0). Of the 263 patients, 87
patients were enrolled onto INTACC 01 and the remaining 176
onto INTACC 02. Patients were very well-balanced in the two arms
of each study.
With regard to the biofunctional characterisation, differing
degrees of tumour lymphocyte inﬁltration were observed in about
87% of cases. The frequency of diploid tumours at ﬂow cytometric
analysis was 44% and, among the 56% of aneuploid tumours, 20%
showed multiple cell clones (data not shown).
MVD ranged from 4 to 95 microvessels mm
72 with a median
value of 24 and VEGF-expressing cells varied from 0 to 100%, with
a median value of 35%. The fraction of TS-expressing cells ranged
from 0 to 90% in the different tumours, with a median value of
15%.
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Table 1 Clinico-pathological and biological characteristics in the case
series
Variables Number of cases %
Age (years)
460 123 47.1
460 138 52.9
Missing 2
Gender
Male 137 52.1
Female 126 47.9
ECOG Performance Status
0 225 85.6
1 38 14.4
Tumour site
Proximal 107 40.7
Distal 156 59.3
Dukes’ Stage
B2–B3 142 54.0
C 121 46.0
Histological grade
Well-moderately differentiated 168 68.0
Poorly differentiated 79 32.0
Missing 16
Lymphocyte inﬁltration
0 33 12.9
1 63 24.6
2 87 34.0
3 73 28.5
Missing 7
Ploidy
Diploid 106 43.6
Aneuploid 137 56.4
Missing 20
MVD mm
72
524 126 50.2
524 125 49.8
Missing 12
VEGF positive cells (%)
535 87 46.5
535 100 53.5
Missing 76
TS positive cells (%)
515 123 47.9
515 134 52.1
Missing 6
Treatment
INTACC01 5fu+leva 44 50.6
5fu+leva+lv 43 49.4
INTACC02 5fu+leva+lv 90 51.1
mtx+5fu+leva 86 48.9
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British Journal of Cancer (2002) 87(8), 868–875 ã 2002 Cancer Research UKImmunostaining intensity was evaluated for both VEGF and TS.
VEGF staining was not observed in 6% of cases, whereas staining
intensities 1, 2 and 3 were found in 34, 44 and 16% of tumours,
respectively. TS immunostaining was not present in 27% of cases
and intensities 1, 2 and 3 were observed in 28, 34 and 11% of
cases, respectively.
A highly signiﬁcant direct relation between the percentage of
immunopositive cells and staining intensity (Figure 1) was
observed for both VEGF and TS. For this reason, only the percen-
tage of immunopositive cells was considered in the subsequent
analyses.
The analysis of age, MVD, TS and VEGF, considered as contin-
uous variables, showed no correlation between any of the markers,
with the exception of a signiﬁcant direct correlation between TS
and age, albeit with a very poor coefﬁcient (rs=0.16) (data not
shown).
The evaluation of the biologic markers in the different
subgroups deﬁned according to clinico-pathological characteristics
showed that MVD median value was signiﬁcantly higher in patients
with an ECOG performance status of 1 than of 0, in proximal
tumours and, unexpectedly, in those with well-moderately rather
than poorly differentiated lesions. A higher median value of
VEGF-expressing cells was observed in males than in females. TS
median value was signiﬁcantly higher in older than in younger
patients and in well-moderately with respect to poorly differen-
tiated lesions. Moreover, TS expression was signiﬁcantly related
to lymphocyte inﬁltration, with a median value 10 times higher
in the absence or presence of a weak compared to massive inﬁltra-
tion. No relation was observed between ploidy and MVD, VEGF or
TS (Table 2).
DFS and OS were analysed as a function of the different vari-
ables in univariate analysis (Table 3). Age, gender and Dukes’
stage showed an impact on DFS, as expected and repeatedly
reported in the literature (Sant, Eurocare Working Group, 1999;
Skibber et al, 2001) with a signiﬁcantly better prognosis for young-
er and female patients and for those with Dukes’ stage B tumours.
Only a slightly better DFS was observed for patients with well-
moderately differentiated or highly vascularized tumours analysed
in a Cox regression model and for those with diploid tumours,
whereas no other biological marker was indicative of DFS.
With regard to OS, the relevance of age and gender was
weakened, whereas it was conﬁrmed for histological grade and
Dukes’ stage. Among the biological variables tested, a trend of
better prognosis was observed for high-massive compared to low
lymphocyte inﬁltration.
When VEGF, MVD, TS were analysed as continuous variables,
the coefﬁcient estimate for each unit increase was not different
from 0 or, from a statistical point of view, did not highlight a role
played by any variable on clinical outcome.
DISCUSSION
Over the last 20 years clinical researchers have tried to identify
biological markers that predict tumour sensitivity or resistance to
clinical therapies and probability of recurrence. Ultimately, their
usefulness in clinical decision-making depends on easy determina-
tion at the lowest possible costs. In colorectal cancer, for example,
some newly proposed and investigated molecular markers, such as
microsatellite instability (Elsaleh et al, 2000; Watanabe et al, 2001),
appear promising, but not all laboratories are equipped for their
determination. For this reason we felt it would be interesting to
investigate a number of easily assessable biofunctional features of
colorectal cancer, paying special attention to the reliability and
reproducibility of determinations.
In our case series the frequency of aneuploid tumours was in
line with the highest values reported in the literature, thus indicat-
ing that no aneuploid populations were lost during methodological
manipulations, notwithstanding the use of parafﬁn-embedded
material (Silvestrini et al, 1993; Flyger et al, 1999; Salud et al,
1999).
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Table 2 Relationship between biologic variables and clinico-pathologic factors
MVD mm
72
median value
(range) P
VEGF positive cells (%)
median value
(range) P
TS positive cells (%)
median value
(range) P
Age (years)
460 24 (6–89) 30 (0–95) 5 (0–90)
460 23 (4–95) 0.754 40 (0–100) 0.204 25 (0–80) 0.009
Gender
Male 24 (4–95) 40 (0–100) 25 (0–90)
Female 22 (5–83) 0.342 30 (0–85) 0.014 10 (0–80) 0.077
ECOG Performance Status
0 22 (4–91) 35 (0–100) 15 (0–90)
1 27 (7–95) 0.019 32 (2–90) 0.741 27.5 (0–85) 0.125
Tumour site
Proximal 27 (6–89) 35 (0–90) 10 (0–90)
Distal 22 (4–95) 0.035 35 (0–100) 0.926 20 (0–80) 0.155
Dukes’ Stage
B2–B3 24 (5–91) 35 (0–95) 20 (0–90)
C 22 (4–95) 0.482 35 (0–100) 0.934 15 (0–80) 0.446
Histological grade
Well-moderately differentiated 25 (4–95) 37.5 (0–100) 25 (0–80)
Poorly differentiated 18 (5–75) 50.001 40 (0–95) 0.923 5 (0–90) 0.013
Lymphocyte inﬁltration
0–1 24 (4–95) 50 (0–100) 50 (0–85)
2–3 22 (5–76) 0.270 30 (0–100) 0.121 5 (0–90) 50.001
Ploidy
Diploid 24 (6–91) 30 (0–100) 15 (0–90)
Aneuploid 23 (4–95) 0.943 40 (0–100) 0.623 17.5 (0–80) 0.693
Biological markers in colon cancer outcome
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tory, showing a statistically signiﬁcant role, a weak or non
independent role or no prognostic relevance on clinical outcome
(Silvestrini et al, 1993; Ratto et al, 1998; Flyger et al, 1999; Salud
et al, 1999; Purdie and Piris, 2000; Skibber, et al, 2001). These
controversial results can be attributed to heterogeneity of case
series in terms of stage and treatment and may also be due to
the length of follow-up. In our case series only a trend of better
DFS, which was not observed for OS, was seen for patients with
diploid tumours.
With regard to the neoangiogenesis process, it has been
hypothesised that, in both experimental and clinical models, the
increase in microvessel density, by favouring drug access, could
be considered as a predictor of response to chemotherapy and
can therefore be associated with a better prognosis. However, there
are no deﬁnitive conclusions on the clinical relevance of MVD in
patients with operable colon cancer treated with antimetabolites
in an adjuvant setting. It is difﬁcult to compare our ﬁndings with
those reported in other studies due to the heterogeneity of case
series with respect to stage and treatment. While some studies
(Bossi et al, 1995; Frank et al, 1995; Mooteri et al, 1996; Takebaya-
shi et al, 1996; Amaya et al, 1997; Takahashi et al, 1997; Banner et
al, 1998; Giatromanolaki et al, 1999; Vermeulen et al, 1999) found
a direct or no relation between high angiogenic activity and poorer
prognosis, we observed a trend of a better prognosis for patients
with high MVD tumours, in agreement with recently published
results obtained on large case series (Lindmark et al, 1996; Abdalla
et al, 1999). Similar results have already been reported in breast
cancer (Protopapa et al, 1993; Axelsson et al, 1995; Medri et al,
2000). Whether this ﬁnding can be attributed to a lower clinical
aggressiveness or to a higher chemosensitivity of high MVD
tumours remains to be ascertained, although the latter hypothesis
appears the most likely.
With regard to VEGF expression (Berney et al, 1998; Ishigami et
al, 1998; Tokunaga et al, 1998; Cascinu et al, 2000; Lee et al, 2000;
Maeda et al, 2000), no differences were observed between DFS and
OS in patients with high or low VEGF-expressing tumours. It is
also worthy of note that, differently from other studies (Amaya
et al, 1997; Takahashi et al, 1997), we did not ﬁnd any relation
between MVD and VEGF expression. In our opinion the two
markers are not necessarily linked to each other. The formation
of new microvessels, and therefore MVD, may be the result of
many factors such as tumour size, stage, presence of necrosis or
ulceration, or levels of angiogenic peptides. Among these, VEGF
is certainly one of the growth factors involved in initiating and
stimulating the formation of intratumoral microvessels, but other
factors may also play a important role.
Few papers have investigated the role of lymphocyte inﬁltration
(Carlon et al, 1984; Svennevig et al, 1984; Jass, 1986; Harrison et al,
1994). In our study, no association was found between the
presence of lymphocyte inﬁltration and clinical outcome, suggest-
ing that the immunological response of the host to the primary
tumour may not be related to metastatic potential, which is known
to be the result of selected cell clones that have acquired the ability
to deceive or overcome the host’s immune strategies.
TS expression has been extensively studied in the last few years
both as a prognostic factor and as a predictor of response to
chemotherapy. Overall, studies have dealt with the relation
between TS expression and clinical outcome of patients in both
adjuvant and advanced settings. In metastatic disease, low TS
levels have consistently been found to be predictive of responsive-
ness to 5-FU-based chemotherapy (Peters et al, 1994; Johnston et
al, 1995; Kornmann et al, 1997; Leichman et al, 1997, Leichman,
1998; Lenz et al, 1998; Aschele et al, 1999; Bathe et al, 1999;
Cascinu et al, 1999; Paradiso et al, 2000; Allegra, 2002). The
situation in the adjuvant setting is less clear (Johnston et al,
1994; Findlay et al, 1997; Yamachika et al, 1998; Sanguedolce
et al, 1998; van Triest et al, 2000; Takenoue et al, 2000; Edler
et al, 2000; Cascinu et al, 2001; Wong et al, 2001; Tomiak et
al, 2001; Allegra et al, 2002). With respect to the real prognostic
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Figure 1 Relationship between staining intensity and percentage of VEGF and TS immunopositive cells.
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studies conducted on mainly small series of patients not treated
with systemic therapy (Yamachika et al, 1998; Sanguedolce et
al, 1998; van Triest et al, 2000; Takenoue et al, 2000; Edler et
al, 2000, 2002) have shown inconclusive results.
In colorectal cancer patients treated with adjuvant 5-FU-
containing chemotherapy, both high (Johnston et al, 1994; Take-
noue et al, 2000; Edler et al, 2002) and low (Cascinu et al, 2001;
Wong et al, 2001) TS expression were found to be associated with
a better clinical outcome. Our results and those of other studies
(Findlay et al, 1997; Yamachika et al, 1998; Tomiak et al, 2001)
did not highlight that TS was capable of predicting clinical
outcome.
In conclusion, our ﬁndings, obtained under strict quality control
conditions for biological determinations and with close patient
follow-up, indicate that MVD, VEGF and TS expression are not
ready for ‘prime time’ and that other markers must be identiﬁed
for a rational management of colon cancer patients.
On the basis of available literature data and in the light of the
results from the present study, it is not possible to draw any deﬁ-
nitive conclusions about the role of the investigated biomarkers in
predicting the clinical outcome of patients with colorectal cancer.
Even though it is not a diffuse custom among clinical researchers,
future investigations should be carefully planned to achieve an
adequate level of evidence that will allow the questions put forward
to be answered.
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Table 3 Four-year disease-free and overall survival as a function of clinico-pathological and biological variables
DFS % OS %
No of cases No of events (95% CI) P No of events (95% CI) P
All 263 94 63 (57–69) 63 78 (73–83)
Age (years)
460 123 36 71 (63–79) 0.023
a 25 81 (74–88) 0.120
460 138 57 55 (46–65) 0.036
b 37 75 (67–82) 0.078
Gender
Male 137 60 54 (45–63) 0.008 39 74 (66–82) 0.089
Female 126 34 73 (65–81) 0.011 24 83 (76–89) 0.052
ECOG Performance Status
0 225 80 63 (56–70) 0.695 53 79 (74–85) 0.484
1 38 14 65 (50–80) 0.652 10 72 (57–87) 0.256
Tumour site
Proximal 107 35 67 (58–76) 0.379 28 74 (65–82) 0.379
Distal 156 59 60 (52–69) 0.269 35 81 (75–88) 0.771
Dukes’ stage
B2–B3 142 37 72 (64–80) 50.001 18 88 (83–94) 50.001
C 121 57 53 (44–62) 0.006 45 67 (58–75) 0.002
Histological grade
Well-moderately differentiated 168 56 66 (59–74) 0.113 31 82 (76–88) 0.003
Poorly differentiated 79 32 57 (46–69) 0.075 28 68 (57–79) 0.005
Lymphocyte inﬁltration
0–1 96 41 58 (47–68) 0.136 30 72 (63–81) 0.060
2–3 160 53 65 (57–73) 0.222 33 81 (75–87) 0.091
Ploidy
Diploid 106 32 68 (59–78) 0.070 23 79 (70–87) 0.443
Aneuploid 137 59 57 (48–66) 0.203 37 77 (70–84) 0.684
MVD mm
72
524 126 51 57 (48–66) 0.142 32 78 (71–86) 0.916
524 125 41 68 (59–76) 0.079 29 78 (70–85) 0.807
VEGF (%)
535 87 31 63 (52–74) 0.634 21 76 (67–85) 0.677
535 100 42 58 (47–68) 0.869 30 74 (64–83) 0.800
TS (%)
515 123 45 64 (55–72) 0.861 32 76 (68–84) 0.913
515 134 49 61 (52–70) 0.868 31 79 (72–86) 0.785
aStratiﬁed by treatment arm.
bAdjusted for Age, Gender, Dukes’ stage, Histological grade in a Cox regression model stratiﬁed by treatment arm.
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